Previous studies have indicated that combined treatment with bortezomib and other drugs such as anti-β2-microglobulin monoclonal antibody [45] and the DNA methyltransferase inhibitor decitabine [46] overcomes bortezomib drug resistance in multiple myeloma and mantle cell lymphoma, respectively. This evidence concerns the gene HLA-G and plasma cell myeloma.